Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 in Relapsed/Refractory Metastatic or Advanced Solid Tumors
NCT05052255Phase 2Terminated
- Sponsor
- Ryvu Therapeutics
- Start
- Aug 2021
- Primary completion
- Oct 2025
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rvu120 in solid tumor and triple-negative breast cancer (TNBC), sponsored by Ryvu Therapeutics. Primary endpoints: Adverse Events up to 2 years, Dose Finding up to 2 years and 4 more. Started Aug 2021; status: terminated.
02
Drugs
rvu120
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05052255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052255.